

# Health screening and selection: Evidence from biennial subsidies in South Korea

Sihoh Park

University of Illinois Urbana-Champaign

December 25, 2023

# Table of Contents

Research question

Institutional background

Identification and data

Results

Effect on take-up

Inter-screening spillover

Spousal spillover

Selection

Effect of screening

Conclusion

# Table of Contents

Research question

Institutional background

Identification and data

Results

Effect on take-up

Inter-screening spillover

Spousal spillover

Selection

Effect of screening

Conclusion

# Motivation

- The goal of health screening is to find diseases early
  - Some cancers are easier to treat when diagnosed early
  - 5 year survival rates show large difference by the stage of cancers
    - Breast cancer: 98% (localized) ⇒ 30% (distant)
    - Lung cancer: 57% (localized) ⇒ 7% (distant)
    - Stomach cancer: 97% (localized) ⇒ 6% (distant) - (Korea)
  - Health screenings are designed to diagnose diseases at an early stage
- Despite wide practice, the evidence on health screenings are mixed
  - Many clinical RCTs on general/cancer screenings find limited impact on mortality ([Krogsbøll et al., 2012](#))
  - Many screening guidelines change due to insignificant impact on mortality
  - One reason is the selection of healthy people participating in screening

# Motivation

- Characteristics of screening participants
  - Symptomatic group: self-aware high risk group
  - Asymptomatic group
    - Participants are from higher socioeconomic background ([Bender et al., 2014](#))
    - Participants are more likely to show other positive health behaviors ([Oster, 2020](#))
    - Participants show lower mortality ([Strandberg et al., 1995](#))
- Policies to better target people who may be carrying a disease but do not yet know about it
  - Age-based recommendation is not well targeted ([Einav et al., 2020](#))
- Another common policy for increasing screening participation: subsidies
  - Low income people might be more sensitive to subsidies
  - Affordable Care Act / National Breast and Cervical Cancer Early Detection Program

# Research question

1. How do subsidies affect screening participation?
  - National Health Screening Program in Korea
  - Subsidies for various screenings (general and cancer screenings)
  - Multiple policies (age-based recommendation, subsidies)
  - Variation in age cutoff and subsidy schedules (biennial, annual)
2. Who responds to screening subsidies?
  - Characterize compliers with respect to age-based recommendation and subsidies
  - Compare compliers with always-takers and never-takers
  - Health conditions / socioeconomic status / health behaviors
3. What is the effect of screening on health care utilizations, diagnoses and mortality?

## Preview of results

1. Biennial subsidies increases screening participation from 10% to 30%
2. There are positive and negative cross-spillover effects between different types of screenings
3. Subsidies increase not only one's own but also the spouse's participation in screening
4. Compared to always-takers, compliers with screening subsidies have lower socioeconomic background and are more likely to be diagnosed with a disease
5. In 1 year of screening, the number of first hospital visits for a new illness, a proxy for new diagnosis, increases significantly

## Contributions to literature

- Health screening decision
- Compliers to different screening policies

# Table of Contents

Research question

**Institutional background**

Identification and data

Results

Effect on take-up

Inter-screening spillover

Spousal spillover

Selection

Effect of screening

Conclusion

# Korean health screening program

- 3 types of screening covered by the National Health Insurance in Korea
  - General health screening
  - Cancer screenings (5 types)
  - Infant/children health screening
- General health screening
  - Most basic tests for health conditions
  - Measurement of height, weight, blood pressure, chest X-ray, dental test, blood test, uroscopy and health risk evaluation
- Cancer screening
  - Stomach cancer screening
  - Breast cancer screening
  - Cervical cancer screening
  - Liver cancer screening
  - Colorectal cancer screening

# Screening subsidy criteria

- Biennial subsidy rule
  - Those born in even years can get subsidized screening in even years
  - Those born in odd years can get subsidized screening in odd years
- Eligible for subsidies during a calendar year when the age is even
  - Age = current year - birth year
  - No subsidy when age is odd
  - Subsidy eligibility switch on and off every year
  - Eligible once every two years
- Age cutoff
  - $\text{Age} \geq 40$ : biennial subsidy
  - $\text{Age} < 40$ : no subsidy

# Variation in subsidy eligibility across screenings

	Biennial				Annual		No-subsidy	
	General	Stomach	Breast	Cervical	Liver	Colorectal	Lung	Prostate
Frequency	2 years	2 years	2 years	2 years	0.5 year	1 year		
Subsidy starting age	40	40	40	30	40	50		
Subsidy amount	100%	90%	90%	100%	90%	90%	0%	0%
Copay (\$)	0	7	3.5	0	10	5	110	20
Target		Female	Female	High risk group			Male	
Subsidized medical tests	Gastroscopy, biopsy	Mammogram	Pap smear	Ultrasound, MSAFP	Fecal occult blood test, colonoscopy, biopsy			

Liver high risk group

# Implementation of the health screening program

- Nationwide program
  - No "outside" of the program
    - ⇒ target: all the citizens covered by National Health Insurance Service (NHIS)
  - Do not examine the introduction of the program
    - ⇒ Comparison between those eligible and ineligible for subsidies
- How to receive subsidized screenings
  - Access point: public health clinics / private clinics and hospitals designated by the NHIS
    - ⇒ (Dec 2023) 5,800 screening centers in Seoul → 900 people per center
  - Appointment: normally required but varies by hospitals and type of screenings
- How was subsidy eligibility conveyed
  - Even-odd subsidy rule has been used since 1980s
  - Reminder mails (and mobile notifications) sent to those eligible for subsidies
  - Mail contains the type of screenings to receive and health care providers in the neighborhood

# Table of Contents

Research question

Institutional background

Identification and data

Results

Effect on take-up

Inter-screening spillover


Spousal spillover

Selection

Effect of screening

Conclusion

# Stomach cancer screening take-up by age



# Conceptual framework for 3 effects

- 2 policies and 3 effects
  - Recommendation effect: increase participation from age 40 regardless of even or odd age
  - Subsidy effect: increase participation at even ages from age 40
  - Substitution effect: move screening from odd to even ages
- Regression discontinuity design at age 40 using 2 year average take-up
  - Increase in participation due to recommendation and subsidies
  - 2-year average take-up cancels out substitution effect
- Comparing even vs odd age group from age 40
  - Increase in participation due to subsidies and substitution
  - Recommendation effect is cancelled out

## Regression discontinuity at age 40 using 2 year bins

- Bin ages by 2 years and use bins as a unit of age
  - Bins: [34, 35], [36, 37], [38, 39], [40, 41], [42, 43], [44, 45]  
⇒ Denote each bin with the midpoint
- Econometric specification

$$screen_{it} = \alpha_0 + \alpha_1 \cdot a_{it} + \alpha_2 \cdot \mathbb{1}\{a_{it} > 0\} + \alpha_3 \cdot a_{it} \times \mathbb{1}\{a_{it} > 0\} + \varepsilon_{it} \quad (1)$$

- $a_{it} = (\text{agebin}_{it} - 39.5)$
- Individual  $i$  in year  $t$
- Analytical sample: age  $\in [34, 45]$
- Standard error clustered at the individual level

# Comparing even vs odd age groups from age 40

- Comparison between even age vs odd age from age 40
  - Variation comes from year of birth being even or odd
- Balance between even (treatment) and odd (control) group
  - Even age (treatment) group is younger than the odd age (control) group
  - Subsidy eligibility is random conditional on  $f(\text{age})$
- Econometric specification

$$y_{it} = \beta_0 + \beta_1 \cdot \text{age\_even}_{it} + f(\text{age}_{it}) + \epsilon_{it} \quad (2)$$

- Individual  $i$  in year  $t$
- Analytical sample:  $\text{age} \in [40, 89]$
- $f(\text{age})$ : linear splines with 5 years interval
- Standard error clustered at the individual level

# Balance table: balanced conditional on f(age)

	(1)	(2)	(3)
	Treatment group	Control group	Conditional difference
Age	58.697 (12.532)	59.240 (12.353)	- -
Female	0.530 (0.499)	0.532 (0.499)	-0.002* (0.001)
Currently married	0.799 (0.401)	0.798 (0.402)	-0.001 (0.001)
Years of education	10.320 (4.510)	10.227 (4.538)	-0.003 (0.008)
Working status	0.610 (0.488)	0.608 (0.488)	-0.003* (0.001)
Individual income	1446.3 (2081.6)	1425.7 (2068.1)	2.8 (5.2)
Household income	4104.4 (3708.6)	4086.7 (3737.9)	3.2 (14.3)
Own a house	0.734 (0.442)	0.737 (0.441)	-0.000 (0.001)
Number of household members	3.067 (1.317)	3.051 (1.317)	-0.004 (0.003)
N	54274	52909	
Share	(0.51)	(0.49)	
F(8, 15939)			1.65 (0.10)

Robustness

Bounding

# Data

- Korean health panel study dataset
  - Annual panel data from 2008 to 2018
  - Household level sampling (7000) / Individual level data (21,300)
  - Survey data collected through face-to-face interview (self-reported)
  - Information on
    - Demographic and SES
    - Health care usage
    - Health behaviors
- **Health care usage (outpatient, inpatient, emergency)**
  - Unit of observations: **every visit to a hospital**
  - Information
    - Date
    - Hospital bills, drug expenditures
    - Type of hospitals visited
    - Diagnosis (ICD-10)
    - First visit vs Recurring visit
    - Health screening records: screening type, tests performed, screening results, disease found

# Table of Contents

Research question

Institutional background

Identification and data

## Results

Effect on take-up

Inter-screening spillover

Spousal spillover

Selection

Effect of screening

Conclusion

# Table of Contents

Research question

Institutional background

Identification and data

## Results

Effect on take-up

Inter-screening spillover


Spousal spillover

Selection


Effect of screening

Conclusion


## General screening - even vs odd age




## General screening - 2 year age bins




## Stomach screening - even vs odd age




## Stomach screening - 2 year age bins




## Breast screening - even vs odd age




## Breast screening - 2 year age bins



## Cervical screening - even vs odd age



## Cervical screening - 2 year age bins



# Regression discontinuity using 2-year age bins

	(1)	(2)	(3)	(4)	(5)
	Any	General	Stomach	Breast	Cervical
Age $\geq$ 40	0.097*** (0.008)	0.086*** (0.007)	0.105*** (0.006)	0.112*** (0.009)	0.074*** (0.010)
Constant	0.121*** (0.005)	0.095*** (0.005)	0.061*** (0.004)	0.064*** (0.005)	0.093*** (0.006)
N	34713	34713	34713	17725	17725
Adj $R^2$	0.017	0.020	0.032	0.037	0.013
Sample age range	[34, 45]	[34, 45]	[34, 45]	[34, 45]	[34, 45]
Subsidy starting age	40	40	40	40	30

# Comparing even vs odd age

	(1)	(2)	(3)	(4)	(5)
	Any	General	Stomach	Breast	Cervical
Age even	0.204*** (0.003)	0.187*** (0.003)	0.190*** (0.003)	0.191*** (0.004)	0.164*** (0.003)
N	107183	107183	107183	56923	56923
Adj $R^2$	0.068	0.061	0.069	0.080	0.074
F-statistic	5012	4804	4830	2904	2520
Sample age range	[40, 89]	[40, 89]	[40, 89]	[40, 89]	[40, 89]
Subsidy starting age	40	40	40	40	30
Age controls	Y	Y	Y	Y	Y
Control group mean	0.122	0.102	0.083	0.067	0.056

Robustness

Bounding

# Intertemporal substitution

- One can move the screening from odd to even age to be eligible for subsidies
  - Intertemporal reallocation can widen the gap between even and odd ages
  - Even/odd comparison captures the sum of subsidy and substitution effect
- Hard to disentangle the subsidy effect from substitution effect
  - Counterfactual: recommendation for biennial screening from age 40 but without subsidies
  - Time periods before and after the introduction of the subsidy policies
  - 2-year binning presents effect size without substitution effect
- Evidence for (the lack of) intertemporal substitution
  1. Ages before and after the introduction of the subsidies (around age 40)
  2. Monthly distribution of screening take-up

⇒ No strong sign of substitution

US mammogram

Around age 40

Screening months

# Table of Contents

Research question

Institutional background

Identification and data

## Results

Effect on take-up

**Inter-screening spillover**


Spousal spillover

Selection


Effect of screening

Conclusion


## Lung screening - no subsidy




## Prostate screening - no subsidy



## Liver screening - annual subsidy



## Colorectal screening - annual subsidy



# Positive inter-screening spillover

	(1)	(2)	(3)
	No subsidy		Annual subsidy
	Lung	Prostate	Colorectal
<b>Panel A. ITT</b>			
Age even	0.006*** (0.001)	0.007*** (0.001)	0.020*** (0.002)
<b>Panel B. LATE</b>			
Biennial screening	0.031*** (0.003)	0.046*** (0.006)	0.115*** (0.011)
N	107183	50260	31089
Sample age range	[40, 89]	[40, 89]	[40, 49]
Subsidy starting age			50
Age controls	Y	Y	Y
Control group mean	0.009	0.009	0.024

Robustness

# Negative inter-screening spillover

	(1)	(2)	(3)
	Annual subsidy		Biennial subsidy
	Liver	Colorectal	Cervical
Age even	0.027*** (0.001)	0.038*** (0.002)	0.177*** (0.006)
Age even × age < 40			-0.135*** (0.008)
N	107183	76094	27714
Sample age range	[40, 89]	[50, 89]	[30, 49]
Subsidy starting age	40	50	30
Age controls	Y	Y	Y
Control group mean	0.028	0.027	

Robustness

Cervical screening

# Mechanisms

- Annual- and no-subsidy screening participants are a subset of biennial-subsidy screening participants No always-takers
- People receive multiple screenings on the same day in one hospital visit
  - Fixed cost in visiting hospital (e.g. travel cost, psychological toll, taking a day off)
- Take-up pattern follows that of general health screening
  - Doctor's recommendation at general health screening

Share (multiple)

Reg (multiple)

Heterogeneity (gender)

# Table of Contents

Research question

Institutional background

Identification and data

## Results

Effect on take-up

Inter-screening spillover

**Spousal spillover**

Selection

Effect of screening

Conclusion

# Spillover in take-up between spouses

- Analytical sample


- Dataset contains all the household members
- Currently married people (50,863 couple pairs)
- Own age  $\geq 40$  & spouse age  $\geq 40$

- Econometric specification

$$y_{it} = \theta \cdot \text{age\_even}_{it} + \sigma \cdot \text{spouse\_age\_even}_{it} + \tau \cdot \text{age\_even}_{it} \times \text{spouse\_age\_even}_{it} + \phi_{it} \quad (3)$$

- $y_{it}$ : own screening take-up of individual  $i$  in year  $t$
- Standard error clustered at couple level
- Variation comes from 4 types of couples with different subsidy compositions

## Comparing between 4 types of couples



# Spousal spillover in take-up

	(1)	(2)	(3)	(4)
Outcome var: Own screening take-up				
Age even	0.214*** (0.006)	0.213*** (0.006)	0.212*** (0.004)	0.212*** (0.004)
Spouse age even	0.016*** (0.005)	0.015*** (0.004)		
Age even × Spouse age even	0.000 (0.009)	0.003 (0.009)		
Spouse screening			0.080*** (0.018)	0.080*** (0.018)
N	79962	79782	79962	79782
Odd/Odd group mean	0.127	0.127	0.127	0.127
Demographic controls		Y		Y
Estimator	OLS	OLS	2SLS	2SLS

In each screening

# Mechanisms

- Wife eligible for subsidies increase husband's screening take-up, but it does not work the other way.

Direction

- Spouses can get screening on the same day.

Share (same day)

Reg (same day)

# Table of Contents

Research question

Institutional background

Identification and data

## Results

Effect on take-up

Inter-screening spillover

Spousal spillover

## Selection

Effect of screening

Conclusion


## Selection into screening

- We care not only the increase in screening participation rate, but the characteristics of participants on the margin (compliers)
- Compliance groups following [Angrist et al. \(1996\)](#)


	Treatment	Control
Always-takers	Yes	Yes
Compliers	Yes	No
Defiers	No	Yes
Never-takers	No	No

- We want the policy to target compliers who are likely to have a disease
- 2 reference groups
  - Compliers vs Always-takers  $\Rightarrow$  composition of screening participants
  - Compliers vs Never-takers  $\Rightarrow$  who shows positive health behavior?

# Compliers are more likely to be diagnosed with a disease than always-takers



# Compliers are more likely to be diagnosed with a disease than always-takers



# 1. Estimate Always- and Never-takers characteristics

- Individually identifiable always- and never-takers

	Treatment group	Control group
Always-takers	Yes	Yes
Compliers	Yes	No
Never-takers	No	No

- Estimating equation

$$y_{it} = \beta_0 + \beta_1 treat_{it} + \beta_2 screen_{it} + \beta_3 treat_{it} \times screen_{it} + \nu_{it} \quad (4)$$

- Average characteristics

- Always-takers:  $g_{AT}(y) = \hat{\beta}_0 + \hat{\beta}_2$
- Never-takers:  $g_{NT}(y) = \hat{\beta}_0 + \hat{\beta}_1$

## 2. Back out complier characteristics

- Treated compliers in the treatment group, untreated compliers in the control group

	Treatment group	Control group
Always-takers	Yes	Yes
Compliers	Yes	No
Never-takers	No	No

- Estimating equation

$$y_{it} = \beta_0 + \beta_1 treat_{it} + \beta_2 screen_{it} + \beta_3 treat_{it} \times screen_{it} + \nu_{it} \quad (5)$$

- Those getting screened in the treatment group

$$\begin{aligned} g_T(y) &= \frac{\pi_{AT}}{\pi_{AT} + \pi_C} g_{AT}(y) + \frac{\pi_C}{\pi_{AT} + \pi_C} g_C^1(y) \\ &= \hat{\beta}_0 + \hat{\beta}_1 + \hat{\beta}_2 + \hat{\beta}_3 \end{aligned}$$


- Those not getting screened in the control group

$$\begin{aligned} g_U(y) &= \frac{\pi_{NT}}{\pi_{NT} + \pi_C} g_{NT}(y) + \frac{\pi_C}{\pi_{NT} + \pi_C} g_C^0(y) \\ &= \hat{\beta}_0 \end{aligned}$$


### 3. Compare compliers to always- and never-takers

- Taking ratios
  - Treated compliers to always-takers:  $g_C^1(y)/g_{AT}(y)$
  - Untreated compliers to never-takers:  $g_C^0(y)/g_{NT}(y)$
- Why differentiate between treated and untreated compliers?
  - Characteristics in the same year
  - Unclear pre-determined characteristics
  - Difference between treated and untreated complier characteristics = LATE
- Minor details in estimation
  - Age = 40
  - Standard error calculated with bootstrap with clustering at individual level (500 replications)


# Compliers vs Always-takers using age 40 discontinuity




# Compliers vs Always-takers by comparing even and odd ages



# Compliers vs Never-takers using age 40 discontinuity



# Compliers vs Never-takers by comparing even and odd ages



# Summary of compliers with subsidies

- Compliers are negatively selected on income
  - Lower SES (income, edu)
  - More likely to be diagnosed with a disease
  - Less likely to smoke, drink and exercise
- Compliers are positively selected on health behaviors
  - Positive correlation in health behaviors ([Oster, 2020](#))
- Opposite selection pattern compared to [Einav et al. \(2020\)](#)
  - [Einav et al. \(2020\)](#): Mammogram starting age recommendation based on medical studies
  - This study: Subsidizing 90-100% of screening costs
    - ⇒ Subsidies better target those who are more likely to benefit from screenings

Literature

[Einav et al. \(2020\)](#)

## Compliers to inter-screening spillover

- Among biennial screening participants, who shows spillover effect and participate in annual- and no-subsidy screenings?
- There are no always-takers (one-sided noncompliance)  
⇒ comparison between compliers and never-takers
- Compliers are
  - Less likely to be diagnosed with a breast and cervical disease
  - More likely to be from higher socioeconomic background
  - More likely to smoke, drink, and exercise

Regression

# Table of Contents

Research question

Institutional background

Identification and data

## Results

Effect on take-up

Inter-screening spillover

Spousal spillover

Selection

Effect of screening

Conclusion

# Effect of screening on diagnoses

- Does health screening lead to new diagnoses?
  - How to measure diagnoses
    - Health screening results
    - **Outpatient care data**
  - Number of first hospital visits for a new illness
    - ⇒ First visit vs recurring visit
    - ⇒ Diagnosis code (ICD-10)
- Two-stage least square estimation

$$y_{it} = \eta + \lambda \cdot screen_{it} + f(age_{it}) + \mu_{it} \quad (6)$$

- $screen_{it}$  is instrumented by  $age\_even_{it}$
- Standard error clustered at individual level
- Westfall-Young adjusted p-values for multiple hypotheses testing ([Jones et al., 2019](#))
- Only capture short-run effect

# Effect of screening on diagnoses

	(1)	(2)	(3)	(4)	(5)
	Control mean	ITT	LATE	Adjusted p-values	N
<b>Panel A. Health care utilizations</b>					
Outpatient visit	20.7796	0.0713 (0.0757)	0.3494 (0.3713)	0.886	107183
Inpatient visit	0.2329	0.0056 (0.0039)	0.0272 (0.0192)	0.702	107183
Emergency visit	0.1252	-0.0024 (0.0026)	-0.0117 (0.0127)	0.886	107183
<b>Panel B. First outpatient visits</b>					
First outpatient visit	3.9160	0.0607*** (0.0152)	0.2976*** (0.0747)	0.003	107183
First outpatient visit for a cancer	0.0160	0.0029*** (0.0011)	0.0143*** (0.0055)	0.123	107183
Stomach cancer	0.0023	0.0007 (0.0004)	0.0037 (0.0024)	0.675	107183
Breast cancer	0.0033	0.0016** (0.0008)	0.0086** (0.0042)	0.352	56923
Cervical cancer	0.0003	-0.0001 (0.0002)	-0.0007 (0.0009)	0.886	56923
Liver cancer	0.0009	0.0002 (0.0003)	0.0071 (0.0104)	0.886	107183
Colorectal cancer	0.0019	0.0005 (0.0004)	0.0150 (0.0126)	0.807	107183
Lung cancer	0.0020	0.00001 (0.00042)	0.0011 (0.0666)	0.988	107183
Prostate cancer	0.0032	-0.0011 (0.0007)	-0.1525 (0.0994)	0.675	50260

## Effect of screening on short-term mortality

- National Vital Statistics death certificate data
  - All individual level deaths (1997-2017)
  - Death age
  - Cause of deaths
- Registered population data
  - Population for each age and year
- Reduced form regression

$$mort_{ay} = \nu + \omega \cdot age\_even_a + f(age_a) + \xi_{ay} \quad (7)$$

- Mortality: number of deaths per 1,000 people
- Weighted by population
- Robust standard errors used
- Short-term effect within at most 1 year

## Effect of screening on short-term mortality

	(1)	(2)	(3)	(4)
	Total	Cancer	Cardiovascular	Other
Age even	0.035 (0.169)	0.007 (0.036)	0.008 (0.064)	0.020 (0.081)
N	945	945	945	945
Age controls	Y	Y	Y	Y
Control group mean	20.053	6.684	6.684	6.684

# Table of Contents

Research question

Institutional background

Identification and data

Results

Effect on take-up

Inter-screening spillover

Spousal spillover

Selection

Effect of screening

Conclusion

## Conclusion

1. Biennial screening policy **raises screening rate** by 20%P from 12%.
2. There is **spillover in take-up** across different types of screening and between spouses.
3. Subsidizing screening induces **compliers negatively selected on income and health conditions** compared to always-takers.
4. Subsidizing screening **increases first hospital visits for new diseases.**

## References

- Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996). Identification of causal effects using instrumental variables. *Journal of the American statistical Association*, 91(434):444–455.
- Bender, A. M., Jørgensen, T., Helbech, B., Linneberg, A., and Pisinger, C. (2014). Socioeconomic position and participation in baseline and follow-up visits: the inter99 study. *European journal of preventive cardiology*, 21(7):899–905.
- Einav, L., Finkelstein, A., Ostrom, T., Ostriker, A., and Williams, H. (2020). Screening and selection: The case of mammograms. *American Economic Review*, 110(12):3836–70.
- Howard, D. H., Richardson, L. C., and Thorpe, K. E. (2009). Cancer screening and age in the united states and europe. *Health Affairs*, 28(6):1838–1847.
- Jones, D., Molitor, D., and Reif, J. (2019). What do workplace wellness programs do? evidence from the illinois workplace wellness study. *The Quarterly Journal of Economics*, 134(4):1747–1791.
- Kim, H. B., Lee, S. A., and Lim, W. (2019). Knowing is not half the battle: Impacts of information from the national health screening program in korea. *Journal of health economics*, 65:1–14.
- Kim, H. B. and Lee, S.-m. (2017). When public health intervention is not successful: Cost sharing, crowd-out, and selection in korea's national cancer screening program. *Journal of health economics*, 53:100–116.
- Krogsbøll, L. T., Jørgensen, K. J., Larsen, C. G., and Gøtzsche, P. C. (2012). General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. *Bmj*, 345.
- Oster, E. (2020). Health recommendations and selection in health behaviors. *American Economic Review: Insights*, 2(2):143–60.
- Strandberg, T. E., Salomaa, V. V., Vanhanen, H. T., Naukkarinen, V. A., Sarna, S., and Miettinen, T. A. (1995). Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the helsinki businessmen study. *Heart*, 74(4):449–454.

# High risk group for liver screening

1. Individuals with the following diseases
  - Cirrhosis
  - Chronic liver disease
2. Individuals who were diagnosed with positive results in the previous year general health screening
  - Hepatitis B surface antigen test
  - Hepatitis C virus HCV antibody test

⇒ can be found through blood test
3. Individuals who used medical services for the following diseases in the past two years are excluded
  - Liver cell carcinoma, hepatocellular carcinoma and liver cancer (C22.0)
  - Intrahepatic bile duct carcinoma and Cholangiocarcinoma (C22.1)

back


# Previous studies

- $>^{Kim}$ : Kim and Lee (2017)
- $>^{Einav}$  : Einav et al. (2020)
- $>^{Kw}$ : Kowalski (2023)

	Always-takers	Compliers	Never-takers
Health conditions (Cancer incidence, all-cause mortality)		$\triangleright^{Kim}$ $\triangleleft^{Einav}$ $\triangleright^{Park}$	$\triangleright^{Kim}$ $\triangleright^{Einav}$ $\triangleright^{Kw}$
Socioeconomic status (Income, education)		$\approx^{Einav}$ $\triangleright^{Park}$	$\triangleright^{Einav}$ $\approx^{Park}$
Health Behaviors (Smoking, drinking)		$\triangleright^{Kw}$ $\approx^{Einav}$ $\triangleright^{Park}$	$\triangleright^{Kw}$ $\triangleright^{Einav}$ $\triangleright^{Park}$

back

## First stage by birth year



back

## Comparison with administrative dataset

	Health panel survey	Administrative panel
N / year	18,000	1,000,000
Used by		<a href="#">Kim and Lee (2017)</a> <a href="#">Kim et al. (2019)</a>
Unit of sampling	Household	Individual
Health behavior	Every year	Conditional on screening
First visit for an illness	Yes	No
Demographic & SES	Detailed	Limited

back

## Health care usage data collection

- Recording health care usage
  - Survey participants are asked to keep health diary and store receipts from every visit to hospitals and pharmacies
- No gap
  - During annual interviews, enumerator goes through health diary from the last time of interview

# Health diary

## ❶ 건강기록부 작성방법 ❶

### ❷ 병의원에 다녀왔을 때

- ▶ 우리 가족 누구든지 병의원에 다녀오면 가계부를 작성해주세요.
- ▶ 병의원 영수증과 처방전 및 약국 영수증은 영수증 보관함에 함께 모아주세요.

<작성 예시> 이를 흥길동이 이비인후과에 비염 때문에 다녀온 후

의료 이용 형태	<input checked="" type="checkbox"/> 외래	<input type="checkbox"/> 입원	<input type="checkbox"/> 응급	<input type="checkbox"/> 건강진진
진료 일	2019년 4월 10일(화)			
가구 원 이동	동일동			
병의원 이름	흔흔한 이비인후과			
방문 이유	알레르기 비염			
병원 수납금액	4,000 원			
교통수단 (버스, 택시, 도보 등)	내원	걸어서	외가	걸어서
보관 여부	<input checked="" type="checkbox"/> 진료비 납입 영수증	<input type="checkbox"/> 처방전	<input checked="" type="checkbox"/> 약국불통	

### ❸ 의약품 및 보건의료용품을 삼을 때

- ▶ 우리 가족 누구든지 처방전 없이 의약품 또는 의료기기, 건강기능식품 등을 구매하면 가계부에 기입해주세요.
- ▶ 다음과 같은 항목을 구매한 경우 활별로 합산하여 기입해주세요.
- ▶ 구입영수증은 영수증 보관함에 따로 모아주세요.

<예시> 정파와 함께 먹으려고 멀티비타민 구입. 갑자기 기운이 있어 엄마가 종합건강제를 먹으려서 구매

2019년 5월		
구입목록	구입 장소	비용
1. 일반음식물/약품	<input type="checkbox"/> 병원 <input type="checkbox"/> 약국 <input type="checkbox"/> 마트/편의점	( ) 원
2. 한약 및 한약재 (처방 한약 제외)	<input type="checkbox"/> 약국 <input type="checkbox"/> 한약방	( ) 원
3. 건강보조식품 (홍삼, 비타민 등)	<input type="checkbox"/> 병원과 약국 <input checked="" type="checkbox"/> 인터넷 및 품소통 <input type="checkbox"/> 백화점, 마트, 시장 등	( ) 원 ( ) 원
4. 의약기기 및 의료용품		( ) 원
※ 예시		
<ul style="list-style-type: none"> <li>- 보건의료소모품(绷带, 마스크, 액정수, 연대, 모기기, 고체제)</li> <li>- 안경 및 관제안경은 구입 및 수리</li> <li>- 보청기 구입 및 수리</li> <li>- 신약보조제(당뇨기 등) 개요 영수증을 구매, 대여 및 수리 (체크아웃, 신약 분실증, 책임, 속주 고장기, 불값기, 불상속장기 등)</li> </ul>		

## <How to write health diary>

### • Visit to hospital

- Record it for all the household members
- Store hospital receipts, prescriptions and pharmacy receipts in a box

<Example> After a visit to ENT for allergy

Type	<input checked="" type="checkbox"/> Outpatient	<input type="checkbox"/> Inpatient	<input type="checkbox"/> Emergency	<input type="checkbox"/> Screening
Date	From: April 10, 2019 To:			
Name	John Doe			
Name of the hospital	Dr. Jane M. Doe, MD			
Purpose	Allergy			
Hospital bills	\$40			
Transportation	To	Walking	From	Walking
Receipts	<input type="checkbox"/> Hospital	<input type="checkbox"/> Prescription	<input type="checkbox"/> Pharmacy	

### • Purchase of OTC drugs, oriental medicine, dietary supplements

- Record it for all the household members
- Store hospital receipts, prescriptions and pharmacy receipts in a box

<Example> Purchase of multivitamin and Tylenol


January 2019		
Item	Place	Cost
OTC drugs	<input type="checkbox"/> Hospital <input type="checkbox"/> Pharmacy <input type="checkbox"/> CVS	( ) KRW ( ) KRW ( ) KRW
Oriental medicine	<input type="checkbox"/> Pharmacy <input type="checkbox"/> Acupuncture clinic	( ) KRW ( ) KRW
Dietary supplement (ginseng, vitamin, etc)	<input type="checkbox"/> Hospital or pharmacy <input type="checkbox"/> Internet shopping <input type="checkbox"/> Department store	( ) KRW ( ) KRW ( ) KRW
Any other medical products (e.g.)		( ) KRW
- Bandage, mask, insect repellent		
- Glasses, contact lenses		
- Hearing aid		

back

# Breast screening in the US and Europe (Howard et al., 2009)

## EXHIBIT 3

### Receipt Of Mammography In The Past Two Years Among Women Ages 44–94 In Europe And The United States, By Age Group, 2004




**SOURCES:** U.S. screening rates are from the Medical Expenditure Panel Survey (MEPS), the Health and Retirement Study (HRS), and Surveillance, Epidemiology, and End Results (SEER)-Medicare data (SEER-MCR). European rates are from the Survey of Health, Ageing, and Retirement in Europe (SHARE).

# Colorectal screening in the US and Europe (Howard et al., 2009)


## EXHIBIT 4

Receipt Of Colonoscopy, Sigmoidoscopy, And Fecal Occult Blood Tests Among Women And Men Ages 44-94 In The Past Ten Years In Europe And In The Past Five Years In The United States, By Age Group, 2004



**SOURCES:** U.S. screening rates are from the Medical Expenditure Panel Survey (MEPS); and Surveillance, Epidemiology, and End Results (SEER)-Medicare data (SEER-MCR). European rates are from the Survey of Health, Ageing, and Retirement in Europe (SHARE).

## Age distribution for $age \in [40, 89]$



## Robustness: balance table

	(1)	(2)	(3)
	3 years	5 years	7 years
Female	-0.002* (0.001)	-0.002* (0.001)	-0.002* (0.001)
Currently married	-0.001* (0.001)	-0.001 (0.001)	-0.001 (0.001)
Years of education	-0.003 (0.008)	-0.003 (0.008)	-0.003 (0.008)
Working status	-0.003** (0.002)	-0.003* (0.001)	-0.003* (0.001)
Individual income	1.1 (5.3)	2.8 (5.2)	1.2 (5.2)
Household income	0.6 (15.4)	3.2 (14.3)	-4.5 (14.1)
Own a house	-0.000 (0.001)	-0.000 (0.001)	0.000 (0.001)
Number of household members	-0.004 (0.003)	-0.004 (0.003)	-0.004* (0.003)

back

# Bounding: balance table

	(1) Age ∈ [39, 89]	(2) Age ∈ [40, 89]	(3) Age ∈ [41, 89]
Age	0.521*** (0.026)	-0.543*** (0.026)	0.562*** (0.025)
Female	-0.001 (0.001)	-0.002** (0.001)	-0.001 (0.001)
Currently married	-0.001 (0.001)	0.001 (0.001)	-0.002** (0.001)
Years of education	-0.094*** (0.009)	0.093*** (0.009)	-0.107*** (0.010)
Working status	-0.006*** (0.001)	0.001 (0.002)	-0.007*** (0.002)
Individual income	-16.235*** (5.470)	20.607*** (5.508)	-24.789*** (5.618)
Household income	-23.153 (14.766)	17.735 (14.555)	-31.182** (14.995)
Own a house	0.003*** (0.001)	-0.002* (0.001)	0.003** (0.001)
Number of household members	-0.027*** (0.003)	0.016*** (0.003)	-0.034*** (0.003)
N	110121	107183	104153

back

# Robustness: first stage

	(1)	(2)	(3)	(4)	(5)
	Any	General	Stomach	Breast	Cervical
<b>Panel A. Linear splines of age</b>					
Interval 3	0.204*** (0.003)	0.187*** (0.003)	0.189*** (0.003)	0.190*** (0.004)	0.163*** (0.003)
Interval 5	0.204*** (0.003)	0.187*** (0.003)	0.189*** (0.003)	0.191*** (0.004)	0.164*** (0.003)
Interval 7	0.204*** (0.003)	0.187*** (0.003)	0.189*** (0.003)	0.190*** (0.004)	0.164*** (0.003)
<b>Panel B. Linear splines with 5 years interval plus additional covariates</b>					
Full controls	0.204*** (0.003)	0.187*** (0.003)	0.190*** (0.003)	0.191*** (0.004)	0.164*** (0.003)
Individual FE	0.206*** (0.003)	0.189*** (0.003)	0.191*** (0.003)	0.192*** (0.004)	0.165*** (0.003)

back

## Bounding: first stage


	(1)	(2)	(3)
	Age ∈ [39, 89]	Age ∈ [40, 89]	Age ∈ [41, 89]
Any	0.205*** (0.003)	0.204*** (0.003)	0.204*** (0.003)
General	0.187*** (0.003)	0.186*** (0.003)	0.188*** (0.003)
Stomach	0.191*** (0.003)	0.189*** (0.003)	0.190*** (0.003)
Breast	0.192*** (0.003)	0.191*** (0.004)	0.190*** (0.004)
Cervical	0.165*** (0.003)	0.165*** (0.003)	0.162*** (0.003)
N	110121	107183	104153

back


## Tracking cohorts around age 40

- Drop in screening rate in odd age group after 40 is a sufficient sign of intertemporal substitution
- Opposing recommendation effect can increase participation in odd age group canceling out substitution effect
- Shut down recommendation effect by examining people who were already participating in screening before 40
  - Track 4 age cohorts around age 40
  - Common age range 36 - 43
  - Examine those who took up screening at age 36, 37, 38 and 39


## Stomach screening take-up for the 4 cohorts




## Stomach screening take-up for participants at age 36




## Stomach screening take-up for participants at age 37



## Stomach screening take-up for participants at age 38




## Stomach screening take-up for participants at age 39




back

## Months of stomach screening for age [40, 89]



# Months of breast screening for age [40, 89]



# Comparing screening months before and after 40

- Stacked regression

$$screen_{imt} = \gamma_0 + \gamma_1 \cdot after40_{imt} + \gamma_2 \cdot age\_even_{imt} + \sum_{m=2}^{12} month_m \quad (8)$$

$$+ \gamma_3 \cdot after40_{imt} \cdot age\_even_{imt} + \sum_{m=2}^{12} month_m \cdot after40_{imt} + \sum_{m=2}^{12} month_m \cdot age\_even_{imt} \quad (9)$$


$$+ \sum_{m=2}^{12} month_m \cdot after40_{imt} \cdot age\_even_{imt} \quad (10)$$

- Stacked by months  $\Rightarrow$  Unit of observations: individual-month-year
- Sample:  $age \in [20, 89]$
- Standard error clustered at the individual level


## Interpretation of coefficients

- $\sum_{m=2}^{12} month_m \cdot age\_even_{imt}$ 
  - ⇒ comparison between even and odd before 40
  - ⇒ There should be no difference
- $\sum_{m=2}^{12} month_m \cdot above40_{imt}$ 
  - ⇒ comparison between odd ages before and after 40
  - ⇒ Jan/Feb/Nov/Dec should show smallest increase
- $\sum_{m=2}^{12} month_m \cdot after40_{imt} + \sum month_m \cdot after40_{imt} \cdot age\_even_{imt}$ 
  - ⇒ comparison between even ages before and after 40


## Comparison between even and odd before 40




## Comparison of odd age group before and after 40




## Comparison of odd age group before and after 40



## Comparison of **low income** odd age group before and after 40



## Comparison of **high income** odd age group before and after 40



# Robustness: positive inter-screening spillover

	(1)	(2)	(3)
	No subsidy		Annual subsidy
	Lung	Prostate	Colorectal
<b>Panel A. Linear splines of age</b>			
Interval 3	0.006*** (0.001)	0.007*** (0.001)	0.020*** (0.002)
Interval 5	0.006*** (0.001)	0.007*** (0.001)	0.020*** (0.002)
Interval 7	0.006*** (0.001)	0.007*** (0.001)	0.020*** (0.002)
<b>Panel B. Linear splines with 5 years interval plus additional covariates</b>			
Full controls	0.006*** (0.001)	0.007*** (0.001)	0.020*** (0.002)
Individual FE	0.006*** (0.001)	0.007*** (0.001)	0.021*** (0.002)

back

# Robustness: negative inter-screening spillover

	(1)	(2)	(3)	(4)
	Liver	Colorectal	Cervical	
	Age odd	Age odd	Age even	Age even × age < 40
<b>Panel A. Linear splines of age</b>				
Interval 3	-0.027*** (0.001)	-0.038*** (0.002)	0.176*** (0.006)	-0.133*** (0.008)
Interval 5	-0.027*** (0.001)	-0.038*** (0.002)	0.177*** (0.006)	-0.135*** (0.008)
Interval 7	-0.027*** (0.001)	-0.038*** (0.002)	0.177*** (0.006)	-0.134*** (0.008)
<b>Panel B. Linear splines with 5 years interval plus additional covariates</b>				
Full controls	-0.027*** (0.001)	-0.038*** (0.002)	0.179*** (0.006)	-0.136*** (0.008)
Individual FE	-0.028*** (0.001)	-0.038*** (0.002)	0.181*** (0.006)	-0.141*** (0.008)

back

## Bounding: Inter-screening spillover

	(1)	(2)	(3)
	Age ∈ [39, 89]	Age ∈ [40, 89]	Age ∈ [41, 89]
Liver	0.027*** (0.001)	0.027*** (0.001)	0.027*** (0.001)
Colorectal	0.033*** (0.001)	0.033*** (0.001)	0.034*** (0.001)
Lung	0.006*** (0.001)	0.006*** (0.001)	0.007*** (0.001)
Prostate	0.007*** (0.001)	0.007*** (0.001)	0.008*** (0.001)
N	110121	107183	104153

back

## Screening participants in inter-screening spillover

Annual- and no-subsidy screening participants are a subset of biennial subsidy screening participants

- $\Pr(\text{Any biennial screening} = 1 \mid \text{liver screening} = 1) = 0.98$
- $\Pr(\text{Any biennial screening} = 1 \mid \text{colorectal screening} = 1) = 0.96$
- $\Pr(\text{Any biennial screening} = 1 \mid \text{lung screening} = 1) = 0.98$
- $\Pr(\text{Any biennial screening} = 1 \mid \text{prostate screening} = 1) = 0.99$

[back](#)

## Inter-screening spillover: take-up on the same day with general screening

	(1)	(2)	(3)	(4)
	Liver	Colorectal	Lung	Prostate
$\text{Pr}(\text{general} = 1 \mid \text{screen} = 1)$	0.845	0.801	0.703	0.790
$\text{Pr}(\text{same day} \mid \text{screen} = 1, \text{general} = 1)$	0.948	0.856	0.937	0.960
$\text{Pr}(\text{general first} \mid \text{screen} = 1, \text{general} = 1)$	0.035	0.122	0.044	0.024
$\text{Pr}(\text{general later} \mid \text{screen} = 1, \text{general} = 1)$	0.008	0.177	0.004	0.004

back

# Inter-screening spillover: take-up on the same day with general screening

	(1)	(2)	(3)	(4)
	Annual subsidy		No subsidy	
	Liver	Colorectal	Lung	Prostate
<b>Panel A. Outcome: conducted on the same day</b>				
Age even	0.023*** (0.001)	0.024*** (0.001)	0.004*** (0.001)	0.005*** (0.001)
N	107183	107183	107183	50260
Control group mean	0.022	0.017	0.006	0.007
<b>Panel B. Outcome: conducted after general screening</b>				
Age even	0.0013*** (0.0002)	0.0041*** (0.0004)	0.0005*** (0.0001)	0.0001 (0.0001)
N	107183	107183	107183	50260
Control group mean	0.0006	0.0022	0.0002	0.0002
<b>Panel C. Outcome: conducted before general screening</b>				
Age even	0.0003*** (0.0001)	0.0063*** (0.0005)	0.0001** (0.0000)	0.0001 (0.0001)
N	107183	107183	107183	50260
Control group mean	0.0002	0.0029	0.0000	0.0000
Sample age range	[40, 89]	[40, 89]	[40, 89]	[40, 89]
Subsidy starting age	40	50		
Age controls	Y	Y	Y	Y

back

# Inter-screening spillover: heterogeneity by gender

	(1)	(2)	(3)
	Liver	Colorectal	Lung
Age even	0.025*** (0.002)	0.036*** (0.002)	0.007*** (0.001)
Age even × Female	0.002 (0.003)	-0.005* (0.003)	-0.002 (0.001)
Female	-0.017*** (0.002)	-0.012*** (0.002)	-0.008*** (0.001)
N	107183	107183	107183
Control group mean	0.028	0.026	0.009

back

# Tests for colorectal screening (CDC)

Method	Recommended frequency	Description
Fecal occult blood test (FOBT)	Annual	Use the chemical guaiac to detect blood in the stool
Fecal immunochemical test (FIT)	Annual	Use antibodies to detect blood in the stool
FIT-DNA test	Every 3 years	Combine FIT with a test to detect altered DNA in the stool
Flexible sigmoidoscopy	Every 5 years, or every 10 years with a FIT every year	check for polyps or cancer inside the rectum and lower third of the colon with a short, thin, flexible lighted tube
Colonoscopy	Every 10 years	check for polyps or cancer inside the rectum and the entire colon with longer tube
CT Colonography (Virtual Colonoscopy)	Every 5 years	use X-rays and computers to produce images of the entire colon

back

# Spousal spillover in each screening

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
	General	Stomach	Liver	Colorectal	Lung	Breast	Cervical	Prostate
Age even	0.162*** (0.003)	0.163*** (0.003)	0.023*** (0.001)	0.029*** (0.001)	0.005*** (0.001)	0.167*** (0.004)	0.155*** (0.004)	0.007*** (0.001)
Spouse screening	0.059*** (0.017)	0.065*** (0.017)	0.010 (0.008)	0.022*** (0.008)	0.004 (0.004)	0.010 (0.026)	0.003 (0.025)	-0.003 (0.005)
N	101726	101726	101726	101726	101726	50863	50863	50863

back

# Spousal spillover direction

	(1)	(2)	(3)	(4)
	Among wives (husband $\Rightarrow$ wife)		Among husbands (wife $\Rightarrow$ husband)	
Even age	0.220*** (0.004)	0.218*** (0.004)	0.142*** (0.004)	0.141*** (0.004)
Spouse even age	0.007 (0.004)		0.017*** (0.004)	
Spouse checkup		0.048 (0.031)		0.079*** (0.018)
N	50863	50863	50863	50863
Estimator	OLS	2SLS	OLS	2SLS

back

## Spousal spillover: take-up on the same day

	(1)	(2)	(3)	(4)	(5)
	Total	Even/Even	Even/Odd	Odd/Even	Odd/Odd
Pr(same day   both participate)	0.423	0.494	0.303	0.362	0.462
Pr(Spouse first   both participate)	0.114	0.132	0.095	0.105	0.096
Pr(Spouse later   both participate)	0.114	0.134	0.088	0.113	0.091

back

# Spousal spillover by screening day

	(1)	(2)	(3)	(4)	(5)	(6)
	Outcome var: On the same day		Outcome var: In 30 days before spouse		Outcome var: In 30 days after spouse	
Age even	0.002 (0.002)	0.002 (0.002)	0.004*** (0.001)	0.004*** (0.001)	0.004*** (0.001)	0.004*** (0.001)
Spouse age even	0.002 (0.002)	0.002 (0.002)	0.004*** (0.001)	0.004*** (0.001)	0.003*** (0.001)	0.003*** (0.001)
Age even × Spouse age even	0.069*** (0.005)	0.070*** (0.005)	0.014*** (0.002)	0.015*** (0.002)	0.014*** (0.002)	0.015*** (0.002)
N	101726	101493	101726	101493	101726	101493
Odd/Odd group mean	0.029	0.029	0.006	0.006	0.006	0.006
Demographic controls		Y		Y		Y
Estimator	OLS	OLS	OLS	OLS	OLS	OLS

back

# Complier characterization - Diagnoses

	(1)	(2)	(3)	(4)	(5)	(6)
	Average value			Ratio		
	Always-takers	Treated compliers	Untreated compliers	Never-takers	$CP_1/AT$	$CP_0/NT$
<b>Panel A. Diagnoses</b>						
Diagnosed with a disease	0.258 (0.006)	0.399 (0.007)	-	-	1.550*** (0.053)	-
Stomach disease diagnosis	0.171 (0.006)	0.273 (0.006)	-	-	1.594*** (0.074)	-
Breast disease diagnosis	0.022 (0.004)	0.026 (0.003)	-	-	1.180 (0.263)	-
Cervical disease diagnosis	0.069 (0.007)	0.065 (0.006)	-	-	0.950 (0.149)	-
Colorectal disease diagnosis	0.190 (0.011)	0.202 (0.011)	-	-	1.061 (0.104)	-

always never

# Complier characterization - SES

	(1)	(2)	(3)	(4)	(5)	(6)
	Average value			Ratio		
	Always-takers	Treated compliers	Untreated compliers	Never-takers	$CP_1/AT$	$CP_0/NT$
<b>Panel B. SES</b>						
Individual income	2614 (55)	1991 (50)	1949 (53)	2205 (40)	0.762*** (0.018)	0.884*** (0.018)
Household income	5568 (74)	5030 (69)	4997 (95)	4778 (54)	0.903*** (0.014)	1.046** (0.019)
Years of education	14.174 (0.066)	13.880 (0.068)	13.888 (0.081)	13.560 (0.046)	0.979*** (0.006)	1.024*** (0.005)
College graduate	0.388 (0.011)	0.333 (0.010)	0.335 (0.011)	0.333 (0.009)	0.859*** (0.021)	1.006 (0.021)
Working status	0.796 (0.010)	0.713 (0.010)	0.724 (0.012)	0.754 (0.008)	0.896*** (0.013)	0.960*** (0.014)

always never

# Complier characterization - Health behaviors

	(1)	(2)	(3)	(4)	(5)	(6)
	Average value				Ratio	
	Always-takers	Treated compliers	Untreated compliers	Never-takers	$CP_1 / AT$	$CP_0 / NT$
<b>Panel C. Health behaviors</b>						
Current smoker	0.233 (0.010)	0.191 (0.010)	0.171 (0.011)	0.298 (0.009)	0.819*** (0.033)	0.573*** (0.028)
Everyday smoker	0.218 (0.010)	0.181 (0.009)	0.157 (0.011)	0.284 (0.009)	0.830*** (0.034)	0.554*** (0.028)
Current drinker	0.849 (0.009)	0.812 (0.009)	0.797 (0.012)	0.816 (0.007)	0.957*** (0.012)	0.977* (0.013)
Everyday drinker	0.043 (0.005)	0.028 (0.005)	0.035 (0.006)	0.051 (0.004)	0.641*** (0.115)	0.691*** (0.119)
Vigorous exercise	0.310 (0.009)	0.268 (0.009)	0.283 (0.012)	0.264 (0.007)	0.866*** (0.030)	1.071* (0.039)
Moderate exercise	0.456 (0.010)	0.426 (0.010)	0.426 (0.015)	0.389 (0.008)	0.934*** (0.023)	1.096*** (0.034)
Walking	0.791 (0.008)	0.786 (0.008)	0.778 (0.012)	0.753 (0.007)	0.994 (0.011)	1.033** (0.016)

always never

# Complier characterization - Medical tests

	(1)	(2)	(3)
	Average value		Ratio
	Always-takers	Treated Compliers	$CP_1 / AT$
<b>Panel A. Tests covered by NHIS</b>			
Blood/urine/stool/X-ray	0.801 (0.005)	0.886 (0.006)	1.106*** (0.012)
Endoscopy	0.574 (0.007)	0.776 (0.008)	1.352*** (0.024)
Biopsy	0.026 (0.002)	0.031 (0.002)	1.190 (0.153)
<b>Panel B. Tests not covered by NHIS</b>			
Sonogram	0.319 (0.007)	0.275 (0.007)	0.863*** (0.031)
CT	0.042 (0.003)	0.016 (0.002)	0.374*** (0.071)
MRI	0.010 (0.001)	0.006 (0.001)	0.593** (0.180)
PET	0.002 (0.001)	-0.000 (0.000)	-0.229*** (0.266)
EEG	0.002 (0.001)	0.002 (0.001)	0.743 (0.618)
EKG	0.159 (0.005)	0.127 (0.005)	0.794*** (0.048)
Bone density	0.033 (0.003)	0.029 (0.003)	0.857 (0.126)

always never

# Complier characterization - Health care usage & expenditures

	(1)	(2)	(3)	(4)	(5)	(6)
	Average value				Ratio	
	Always-takers	Treated compliers	Untreated compliers	Never-takers	$CP_1/AT$	$CP_0/NT$
<b>Panel A. Health care utilizations</b>						
Outpatient visit	9.098 (0.360)	10.263 (0.350)	10.007 (0.482)	6.532 (0.213)	1.128** (0.058)	1.532*** (0.087)
Inpatient visit	0.089 (0.012)	0.085 (0.011)	0.057 (0.020)	0.117 (0.009)	0.954 (0.167)	0.481*** (0.176)
Emergency visit	1.221 (0.055)	1.211 (0.064)	1.356 (0.096)	1.332 (0.050)	0.992 (0.043)	1.018 (0.068)
<b>Panel B. Health care expenditures</b>						
Outpatient expenditure	294931 (13122)	280914 (13001)	301873 (19773)	161079 (7445)	0.952 (0.064)	1.874*** (0.147)
Inpatient expenditure	67598 (15311)	75791 (13440)	97104 (28395)	79261 (9612)	1.121 (0.347)	1.225 (0.400)
Emergency expenditure	3467 (713)	4475 (821)	4642 (1742)	3811 (584)	1.291 (0.365)	1.218 (0.539)

always never

# Inter-screening spillover compliers

	(1)	(2)	(3)
	Annual	No-subsidy	Sample mean
<b>Panel A. Diagnoses</b>			
Breast disease diagnosis	-0.006*	-0.019*** (0.004)	0.022
Cervical disease diagnosis	-0.018*** (0.006)	-0.022 (0.016)	0.062
<b>Panel B. SES</b>			
Individual income	873*** (49)	1505*** (110)	1595
Household income	1008*** (66)	1392*** (146)	4570
Years of education	0.971*** (0.072)	1.352*** (0.127)	10.778
College graduate	0.074*** (0.007)	0.131*** (0.014)	0.197
Working status	0.064*** (0.008)	0.142*** (0.012)	0.634

back

# Inter-screening spillover compliers

	(1)	(2)	(3)
	Annual	No-subsidy	Sample mean
<b>Panel C. Health behaviors</b>			
Current smoker	0.044*** (0.006)	0.117*** (0.013)	0.146
Everyday smoker	0.041*** (0.006)	0.101*** (0.013)	0.138
Current drinker	0.066*** (0.008)	0.150*** (0.012)	0.655
Everyday drinker	0.018*** (0.004)	0.034*** (0.009)	0.060
Vigorous exercise	0.050*** (0.007)	0.106*** (0.014)	0.235
Moderate exercise	0.049*** (0.008)	0.108*** (0.015)	0.409
Walking	0.012** (0.006)	0.030*** (0.010)	0.812

back

# Screening results

- Screening results

- Find any disease? ⇒ Which disease? (ICD-10)
- Multiple answers allowed
- Not available for never-takers

Screening	Take-up	Find a disease	ICD-10 codes
Find disease		32.6%	
Stomach	17.8%	22.8%	ICD-10
Breast	16.3%	2.2%	ICD-10
Cervical	13.9%	6.2%	ICD-10
Colorectal	4.3%	19.8%	ICD-10

back

## Disease classifications for stomach

- (K29) Gastritis and duodenitis
- (K52) Other noninfective gastroenteritis and colitis
- (K21) Gastro-oesophageal reflux disease
- (K25) Gastric ulcer
- (B98) Helicobacter pylori
- (K31) Other diseases of stomach and duodenum
- (K20) Esophagitis
- (C16) Malignant neoplasm of stomach
- (K26) Duodenal ulcer

back

## Disease classifications for breast

- (N63) Unspecified lump in breast
- (N64) Other disorders of breast
- (D24) Benign neoplasm of breast
- (N60) Benign mammary dysplasia
- (C50) Malignant neoplasm of breast

[back](#)

## Disease classifications for female reproductive system


- (N76) Other inflammation of vagina and vulva
- (N71) Inflammatory disease of uterus, except cervix
- (N85) Other noninflammatory disorders of uterus, except cervix
- (N83) Noninflammatory disorders of ovary, fallopian tube and broad ligament

[back](#)

## Disease classifications for colon and rectum

- (K63) Other diseases of intestine
- (D12) Benign neoplasm of colon, rectum, anus and anal canal
- (D13) Benign neoplasm of other and ill-defined parts of digestive system
- (R19) Other symptoms and signs involving the digestive system and abdomen
- (C18) Malignant neoplasm of colon

[back](#)



Panel A. Share of mammograms that are true positive and false positive

